Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH.

Laboratoire d'Hépato-Gastroentérologie, EA1186, Faculté Médecine de Nice, Nice, France.
Gastroenterology (Impact Factor: 13.93). 09/2006; 131(3):788-96. DOI: 10.1053/j.gastro.2006.07.007
Source: PubMed

ABSTRACT Hepcidin is an acute-phase response peptide. We have investigated the possible involvement of hepcidin in massive obesity, a state of chronic low-grade inflammation. Three groups of severely obese patients with or without diabetes or nonalcoholic steatohepatitis were investigated.
Hepcidin expression was studied in liver and adipose tissue of these patients. Hepcidin regulation was investigated in vitro by adipose tissue explant stimulation studies.
Hepcidin was expressed not only in the liver but also at the messenger RNA (mRNA) and the protein levels in adipose tissue. Moreover, mRNA expression was increased in adipose tissue of obese patients. The presence of diabetes or NASH did not modify the hepcidin expression levels in liver and adipose tissue. In adipose tissue, mRNA expression correlated with indexes of inflammation, interleukin-6, and C-reactive protein. Interleukin-6 also promoted in vitro hepcidin expression. A low transferrin saturation ratio was observed in 68% of the obese patients; moreover, 24% of these patients presented with anemia. The observed changes in iron status could be due to the role of hepcidin as a negative regulator of intestinal iron absorption and macrophage iron efflux. Interestingly, a feedback control mechanism on hepcidin expression related to low transferrin saturation occurred in the liver but not in the adipose tissue.
Hepcidin is a proinflammatory adipokine and may play an important role in hypoferremia of inflammation in obese condition.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the relationship between changes in serum ferritin concentrations and the development of metabolic syndrome (MetS) and its components over a 6.5 year follow-up period in Finnish adults.
    Diabetology and Metabolic Syndrome 01/2014; 6(1):114. · 2.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Inflammation is thought to be involved in the pathogenesis of obstructive sleep apnea syndrome (OSAS). Hepcidin, a 25-kD peptide hormone produced by the liver, modulates acute inflammatory responses. This study aimed to determine the association of serum levels of hepcidin with the presence and severity of OSAS. Material and Methods We enrolled 184 patients with OSAS and 110 healthy subjects. Serum levels of hepcidin were evaluated using enzyme-linked immunosorbent assay (ELISA) method. Results OSAS patients had significantly higher serum hepcidin levels compared with healthy controls. Multivariable logistic regression analysis indicated that serum hepcidin levels were an independent determinant of the presence of OSAS (OR 1.224, 95% CI 1.159-1.292; P<0.001). Serum hepcidin levels were significantly elevated in severe OSAS patients compared with mild and moderate OSAS patients. Spearman correlation analysis revealed that serum hepcidin levels were correlated with the severity of OSAS. In addition, serum levels of hepcidin were correlated with apnea-hypopnea index (AHI) in patients with OSAS. Conclusions Elevated serum hepcidin levels are associated with the presence and severity of OSAS.
    Medical science monitor: international medical journal of experimental and clinical research 01/2015; 21:27-31. · 1.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepcidin has a regulatory role in inflammation, the immune system, and iron metabolism. It has been shown that proinflammatory cytokine interleukin 6 (IL-6) is an important inducer of hepcidin synthesis during infection and inflammation. Aim of the work To study the relationship between serum hepcidin level and hypoxemia in the COPD patients and its relation to COPD severity. Patients and methods A prospective case control study to compare serum hepcidin levels and other parameters in 70 COPD patients treated at the Pulmonology Department, King Fahad Hospital Dammam, with 34 age and sex matched healthy controls. All subjects participating in the study underwent a complete physical examination and detailed pulmonary function tests (PFTs). A sample from the radial artery for arterial blood gas analysis was done. As well as a panel of other tests including hemoglobin, hematocrit (hct), Iron, CRP, ferritin and total iron binding capacity. A hepcidin prohormone enzyme immunoassay kit (RE 54051, IBL) was used for serum hepcidin measurement. Results COPD patients had significantly lower serum hepcidin level compared to the control group (204.60 ± 53.12 and 280.81 ± 50.61, respectively). Furthermore there was a significantly greater reduction in serum hepcidin level in patients with severe COPD compared to patients with mild COPD. A positive correlation was found between serum hepcidin levels and arterial oxygen saturation (SaO2, %) and FEV1 level (P = 0.005). There was a negative correlation between serum hepcidin level and the ages of patients and packs of cigarettes consumed per year (P = 0.003). Conclusion Our study demonstrated a significant reduction in serum hepcidin levels in COPD patients, and the degree of reduction correlated with the severity of COPD and hypoxemia.
    Egyptian Journal of Chest Diseases and Tuberculosis. 10/2014;


Available from
May 23, 2014

Similar Publications